Sun Pharmaceutical Agrees To Settle Out Of Court with Novartis over Exelon (India)
This article was originally published in PharmAsia News
Executive SummarySun Pharmaceutical Industries agreed to an out-of-court settlement with Novartis over the Indian drug maker's efforts to market a generic of the Novartis drug Exelon (rivastigmine tartrate) for treating Alzheimer's disease. In doing so, Sun joins several other major Indian generics makers in agreeing to an out-of-court settlement with Novartis over Exelon. Sun won U.S. FDA fast-paced approval as the first generic to file, but it and Ranbaxy Laboratories and Dr. Reddy's, as well as U.S.-based Watson Pharmaceuticals, challenged the Novartis patent for Exelon and since reached settlements. Most of the settlements have allowed the generics to market their versions if the innovator gets a share. (Click here for more
You may also be interested in...
The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.
Korean vaccine specialist SK Bioscience moves to develop versatile platform technology to deal with outbreaks of infectious diseases such as the new coronavirus, as the number of infections in the country surges.
Israel-based Binah.ai hopes to earn regulatory approval for a video-based monitoring app that can detect vital signs in minutes. See what Binah.ai's co-founder and CEO, David Maman, said about the technology here.